LanternPharma’s zeta.ai goes live

Lantern Pharma said Tuesday that withZeta.ai is now commercially live, turning the company’s internal cancer research software into a subscription product. (ir.lanternpharma.com) The Dallas company said subscriptions are open now in introductory, academic, and commercial tiers through withzeta.ai. It plans a private demonstration at Nasdaq MarketSite in New York on April 16, 2026, followed by public demos at Booth 5054 during the American Association for Cancer Research annual meeting in San Diego from April 17 to April 22. (ir.lanternpharma.com) (aacr.org) Drug discovery software tries to narrow a huge search problem: which molecules might work, in which tumors, and for which patients. Lantern said withZeta.ai uses multiple specialized artificial intelligence agents that query databases, analyze evidence, and help design molecules and clinical trial plans for rare cancers. (businesswire.com) (ir.lanternpharma.com) Rare cancers are especially hard to study because each tumor type appears in relatively small numbers, which means fewer patients, smaller datasets, and thinner commercial incentives. The Rare Cancer Research Foundation says the National Cancer Institute definition covers cancers with fewer than 15 cases per 100,000 people each year. (rarecancer.org) Lantern is pitching the software as an extension of RADR, the company’s in-house oncology data platform. On its investor site, the company says RADR contains more than 200 billion oncology-focused data points used to match genomic patterns with drug response and to reposition failed compounds. (ir.lanternpharma.com) The company has been building that pitch alongside its own drug pipeline, not as a stand-alone software startup. In an April 2 briefing notice, Lantern said it has earned 12 Food and Drug Administration designations across orphan, pediatric rare disease, and fast track categories, and has dosed more than 100 patients across three precision oncology programs. (businesswire.com) Lantern has also tied the software story to its finances. The company said the subscriptions create a non-dilutive revenue stream, meaning software sales could bring in cash without issuing new shares. (ir.lanternpharma.com) That makes this launch a test of whether biotech investors and research groups will pay for multi-agent software as a lab assistant, not just as an internal tool. Lantern’s first public answers should come this week, on a Nasdaq stage and then on an exhibition floor full of cancer researchers. (ir.lanternpharma.com) (aacr.org)